Pharmacogenetics and the prevention of mother-to-child transmission of HIV

by Cressey T.R., Lallemant M.
Published 2014

Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants

by Prasitwattanaseree S., Lallemant M., Costagliola D., Jourdain G., Mary J.-Y.
Published 2014

Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients

by Cressey T.R., Nangola S., Tawon Y., Pattarawarapan M., Lallemant M., Tayapiwatana C.
Published 2014

A sample size calculation of Bayesian design for superiority trials with rare events

by Sripan P., Ingsrisawang L., Amzal B., Le Ccur S., Cressey T., Lallemant M., Urien S.
Published 2017

Envelope glycoproteins of Human Immunodeficiency Virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties

by Thenin S., Samleerat T., Tavernier E., Ngo-Giang-Huong N., Jourdain G., Lallemant M., Barin F., Braibant M.
Published 2014

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults

by Sirirungsi W., Urien S., Urien S., Urien S., Harrison L., Harrison L., Kamkon J., Kamkon J., Tawon Y., Tawon Y., Luekamlung N., Thongpaen S., Nilmanat A., Jourdain G., Jourdain G., Jourdain G., Lallemant M., Lallemant M., Lallemant M., Le Coeur S., Le Coeur S., Le Coeur S., Ngo-Giang-Huong N., Ngo-Giang-Huong N., Ngo-Giang-Huong N., Owen A., Cressey T., Cressey T., Cressey T.
Published 2015

Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand

by Briand N., Le Coeur S., Jourdain G., Hotrawarikarn S., Sirinontakan S., Hinjiranandana T., Kanjanavanit S., Traisathit P., McIntosh K., Lallemant M.
Published 2014

Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand

by Briand N., Le Coeur S., Jourdain G., Hotrawarikarn S., Sirinontakan S., Hinjiranandana T., Kanjanavanit S., Traisathit P., McIntosh K., Lallemant M.
Published 2014

Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand

by Briand N., Pornprasert S., Ngo-Giang-Huong N., Galacteros F., Pissara S., Tatu T., Sanguansermsri T., Jourdoin G., Lallemant M., Le Coeur S.
Published 2014

Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV

by Traisathit P., Mary J.Y., Le Coeur S., Thantanarat S., Jungpichanvanich S., Pornkitprasarn W., Gomutbutra V., Matanasarawut W., Wannapira W., Lallemant M.
Published 2014

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand

by Duong T., Jourdain G., Ngo-Giang-Huong N., Le Coeur S., Kantipong P., Buranabanjasatean S., Leenasirimakul P., Ariyadej S., Tansuphasawasdikul S., Thongpaen S., Lallemant M.
Published 2014

Predictors of 5-years mortality in HIV-infected adults starting highly active antiretroviral therapy (HAART) in Thailand

by Fregonese F., Collins IJ., Jourdain G., Lecoeur S., Cressey TR., Ngo-Giang-Houng N., Banchongkit S., Chutanunta A., Techapornroong M., Lallemant M.
Published 2014

Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand

by Collins I., Cairns J., Le Coeur S., Pagdi K., Ngampiyaskul C., Layangool P., Borkird T., Na-Rajsima S., Wanchaitanawong V., Jourdain G., Lallemant M.
Published 2014

Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected thai patients receiving indinavir boosted with ritonavir

by Cressey T.R., Urien S., Hirt D., Halue G., Techapornroong M., Bowonwatanuwong C., Leenasirimakul P., Treluyer J.-M., Jourdain G., Lallemant M.
Published 2014

Estimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution model

by Chaillon A., Samleerat T., Zoveda F., Ballesteros S., Moreau A., Ngo-Giang-Huong N., Jourdain G., Gianella S., Lallemant M., Depaulis F., Barin F.
Published 2014

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children

by Cressey T.R., Green H., Khoo S., Treluyer J.-M., Compagnucci A., Saidi Y., Lallemant M., Gibb D.M., Burger D.M.
Published 2014

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy

by Cressey T., Jourdain G., Rawangban B., Varadisai S., Kongpanichkul R., Sabsanong P., Yuthavisuthi P., Chirayus S., Ngo-Giang-Huong N., Voramongkol N., Pattarakulwanich S., Lallemant M.
Published 2017

Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand

by Fregonese F., Collins I.J., Jourdain G., LeCoeur S., Cressey T.R., Ngo-Giang-Houng N., Banchongkit S., Chutanunta A., Techapornroong M., Lallemant M.
Published 2014

Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy

by Collins I.J., Cairns J., Jourdain G., Fregonese F., Nantarukchaikul M., Lertpienthum N., Wannarit P., Attavinijtrakarn P., Layangool P., Le Coeur S., Lallemant M.
Published 2014

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

by Bouazza N., Cressey T., Foissac F., Bienczak A., Denti P., McIlleron H., Burger D., Penazzato M., Lallemant M., Capparelli E., Treluyer J., Urien S.
Published 2017